Logo

GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

Share this

GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

Shots:

  • The approvals are based on the clinical trials to evaluate mepolizumab vs PBO when added to SoC in patients with HES, EGPA & CRSwNP
  • In HES, patients experienced a HES flare (28% vs 56%) @ 32wks. The therapy increased both accrued time in remission & the proportion of patients who achieved remission in patients with EGPA while 70% of patients had a diagnosis of asthma, improvements in the size of nasal polyps @52wks. & in nasal obstruction @49-52wks. along with a reduction in further surgeries @52wks. in patients with CRSwNP
  • Nucala is the 1st anti-IL-5 biologic treatment for HES or CRS with nasal polyps in the EU & is available as a solution in a prefilled pen or syringe or as a powder

Click here to­ read full press release/ article

 Ref: GSK  | Image: GSK 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions